

# Index

## ABANDONMENT

Novelty, nonobviousness and double patenting, **4:65**

## ABBREVIATED NEW DRUG APPLICATION

Infringement, filing ANDA or paper NDA as infringing act, **6:28**

## ACTIVE INDUCEMENT

**Infringement** (this index)

## AMERICA INVENTS ACT (AIA) OF 2011

Derivation proceedings and derived patents suits, **8:38**

Infringement, prior use personal defense, **6:30.50**

Inter partes review, **8:41**

Novelty, nonobviousness and double patenting  
documentary prior art, U.S.  
practice, **4:53**

effect of, **4:27**

introduction, **4:4**

prior art, **4:39**

Office of Patent and Trademark, **8:38 to 8:41**

Post-grant review, **8:40**

Supplemental examination, **8:39**

## AMINO ACID SEQUENCES

**Sequence Listings** (this index)

Office of Patent and Trademark, **App F2(11)**

Representation, **8:11**

## ANCILLARY BIOLOGICAL MATERIALS

Claim drafting, **7:18**

## ANIMALS

Copyright protection for plant and animal phenotypes, **14:10**

Disclosure, animal data, **5:16, 5:17**

## ANIMALS—Cont'd

European Patent Convention, examination guidelines—plant or animal varieties excluded from patentability, **App J3**

Generic Animal Drug and Patent Term Restoration Act, **14:13**

Novelty, nonobviousness and double patenting, animal testing versus clinical testing, **4:59**

PTO notice, animals—patentability, **App H4**

Utility patent protection of animal varieties, **9:3 to 9:6**

## “ANTAMANIDE” CASE

Germany, Federal Republic of, **13:10**

## ANTIBODIES

**Monoclonal Antibodies** (this index)

Patent eligibility issues, **3:7**

## ANTIGENS

Claim drafting, **7:23**

## ANTITRUST MATTERS

Infringement, sham litigation, **6:35**

International matters, **13:13 to 13:17**

Licenses and licensing, **10:32**

## APPLICATIONS

Animal varieties, utility patent protection of, **9:4**

Examining patent applications with respect to 35 U.S.C Section 112, chemical/biotechnical applications, **App H15**

**Office of Patent and Trademark** (this index)

Plant Variety Protection Certificate, **App G4**

## APPRECIATION

Novelty, nonobviousness and double patenting, **4:64**

- ARTICLE 53**  
European Patent Convention, exceptions to patentability, **App J1**
- ARTIFICIAL INTELLIGENCE**  
Novelty, nonobviousness and double patenting, **4:71**
- “ASEXUALLY REPRODUCED” VARIETIES**  
Plants and plant patents, **11:10**
- ASSERTED UTILITY**  
Disclosure, **5:10**
- ASSIGNMENT**  
Ownership, **10:2 to 10:5**
- ATOMIC ENERGY ACT**  
Office of Patent and Trademark, **8:27**
- AUSTRALIA**  
Generally, **13:15**
- AUTHENTICATION**  
Office of Patent and Trademark interference practice, **8:37.40**
- BACTERIA**  
Plants and plant patents, **11:3**
- “BAKER’S YEAST” CASE**  
Germany, Federal Republic of, **13:7**
- BENEFIT TO SOCIETY**  
Disclosure, utility, **5:9**
- BERGY DECISION**  
Patentability of living organisms, **2:4, 2:5**
- “BEST MODE” REQUIREMENT**  
Disclosure, **5:29, 5:30**
- BIOCHEMICALS**  
Patent eligibility issues, **3:8**
- BIOCHEMISTRY CASES**  
Classical biochemistry infringement cases, **6:8**
- BIOLOGICAL PRODUCTS**  
Approval, effect of patents on infringement, biosimilars, **6:33.50**
- BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCIA)**  
Copyright protection, exclusivity, **14:17**
- BIOSIMILARS**  
Approval, effect of patents on infringement, **6:33.50**
- BIOTECHNOLOGICAL PROCESS PATENTS**  
House report on, **App H12**
- BIOTECHNOLOGY CASES**  
Miscellaneous, **4:33**
- BREADTH OF CLAIMS**  
Plants and plant patents, **11:16**
- BREEDING**  
Claim drafting, **7:35**  
Plant breeding, utility patent protection of, **9:2**
- BUDAPEST TREATY**  
**Deposit of Microorganisms** (this index)  
Disclosure, deposits, **5:34, 5:50, 5:55**
- CANADA**  
Microbiology cases, **13:17**
- CCPA**  
Patentability of living organisms, **2:5 to 2:7**
- CELL BIOLOGY CASES**  
Claim drafting, **7:25 to 7:38**  
Classical cell biology infringement cases, **6:9**  
Disclosure, **5:7.10, 5:24, 5:66**  
Living organisms, **3:4**  
Nonobviousness standard, **4:28**
- CELL CULTURES**  
Claim drafting, untransformed eukaryotic cell cultures, **7:37**  
Patents, **1:5, 1:6**
- CELL LINES**  
**Hybridoma Cell Lines** (this index)  
Tangible property rights, **14:11**

## INDEX

### CERTAINTY AND DEFINITENESS

Claim drafting, **7:2 to 7:6**

### CHAKRABARTY DECISION

Patentability of living organisms, **2:3, 2:6, 2:8**

### CHANGES

Plants and plant patents, changes in plant patent protection under UPOV, **11:23**

### CHEMICAL CASES

Nonobviousness standard, **4:35**

### CHEMICAL COMPOSITIONS OR COMPOUNDS

Interim examination guidelines for species claims to chemical compositions based on single prior art reference, **App H14**

Nonobviousness standard, structural similarities of chemical compounds, **4:15**

### CLAIM DRAFTING

Generally, **7:1 et seq.**

Ancillary biological materials, **7:18**

Antigens, **7:23**

Breeding methods, **7:35**

Cell biology inventions, **7:25 to 7:38**

Cell cultures, untransformed eukaryotic cell cultures, **7:37**

Certainty and definiteness, **7:2 to 7:6**

Classification of organisms, **7:4**

Completeness, **7:5**

Construction, **7:8.75**

Cultivation methods, **7:31**

Definiteness requirement, **7:2 to 7:6**

Eukaryotic cell cultures, untransformed eukaryotic cell cultures, **7:37**

Fermentation methods, **7:25 to 7:29**

“Fingerprint” claims, **7:9**

Functional limitations, **7:7**

Genes, structural genes and their proteins, identification of, **7:16**

Genetic engineering methods, **7:17**

Haptens, **7:23**

Hybridoma cell lines, **7:21**

### CLAIM DRAFTING—Cont’d

Identifying structural genes and their proteins, **7:16**

Immunology inventions, **7:19 to 7:24**

Infringement, **7:11**

Isolates, pure cultures of microbial isolates, **7:32**

Isolation methods, **7:31**

“Jepson” claims, **7:14**

Limitations in claims, **7:7 to 7:8.50**

“Markush group” claims, **7:13**

Microbiology inventions, **7:25 to 7:38**

Mixed cultures, **7:33**

Molecular biology inventions, **7:15 to 7:18**

Monoclonal antibodies, **7:20**

Mutated microorganisms, **7:35, 7:36**

Negative limitations in claims, **7:8**

Nutrient media, **7:27**

Office of Patent and Trademark, **8:2 to 8:18.50**

Operating conditions, **7:28**

Organ cultures, **7:38**

“Organism-plus-carrier” claims, **7:34**

Preamble limitations in claims, **7:8.50**

“Product-by-process” claims, **7:10 to 7:12**

Proteins, structural genes and their proteins, identification of, **7:16**

Pure cultures of microbial isolates, **7:32**

Reagents and test kits, **7:24**

Special claim formats, **7:9 to 7:14**

Structural genes and their proteins, identification of, **7:16**

Supplementary protection, **7:29**

Taxonomic classification of organisms, **7:4**

Terms of degree, **7:3, 7:4**

Test kits, **7:24**

Tissue cultures, **7:38**

Untransformed eukaryotic cell cultures, **7:37**

### CLAIMS

As to particular claims, see specific index topics

**CLAIMS—Cont'd**

Drafting. **Claim Drafting** (this index)

**Percentage Sequence Identity Language** (this index)

**CLASSIFICATION OF ORGANISMS**

Claim drafting, **7:4**

**CLASSIFICATION SCHEME**

**Office of Patent and Trademark** (this index)

**CLINICAL MATTERS**

Disclosure, clinical data, **5:15**

Novelty, nonobviousness and double patenting, animal testing versus clinical testing, **4:59**

**COLLABORATION**

Licenses and licensing, **10:25**

**COMPARATIVE STUDY REPORT**

Trilateral Project 24.1, comparative study on biotechnology patent practices, **App J5**

**COMPLETENESS**

Claim drafting, **7:5**

**COMPUTER-IMPLEMENTED STEPS**

Processes involving, patent eligibility issues, **3:14**

**CONCEALMENT**

Novelty, nonobviousness and double patenting, **4:65**

**CONCEPTION**

Novelty, nonobviousness and double patenting, **4:62**

Plants and plant patents, **11:13**

**CONFERENCES**

Novelty, nonobviousness and double patenting, **4:47**

**CONFIDENTIAL DOCUMENTS**

Novelty, nonobviousness and double patenting, **4:49**

**CONSENT**

Infringement, Federal authorization and consent, **6:32**

**CONSIDERATION**

Licenses and licensing, **10:19 to 10:23**

**CONSOLIDATION OF PROCEEDINGS**

Patentability of living organisms, **2:7**

**CONSTITUTIONAL LAW**

Animal varieties, utility patent protection of, **9:3**

**CONSTRUCTION AND INTERPRETATION**

Claim drafting, **7:8.75**

Infringement litigation, interpretation of claim in, **6:8 to 6:13**

Literal infringement, **6:2**

Patentability of living organisms, static v. dynamic construction, **2:11**

**CONTINUED EXAMINATION**

Office of Patent and Trademark, **8:33**

**CONTRACTOR IMMUNITY**

Pandemic Readiness and Emergency Preparedness Act infringement, **6:36**

**CONTRIBUTORY INFRINGEMENT**

**Infringement** (this index)

**CONVENTIONS**

Disclosure, deposits under, **5:60, 5:61**

**European Patent Convention** (this index)

Plant patent protection outside of conventions, **13:4**

**COPYRIGHT PROTECTION**

Animal phenotypes, **14:10**

Biologics Price Competition and Innovation Act (BPCIA), **14:17**

DNA sequences, **14:3 to 14:6**

Gene sequences or molecules, **14:2 to 14:9**

## INDEX

### COPYRIGHT PROTECTION

#### —Cont'd

- Molecules, **14:2 to 14:9**
- Novel gene sequences, **14:5, 14:9**
- Nucleotide combinations, **14:8**
- Plant and animal phenotypes, **14:10**
- Proteins, **14:6**

### CORROBORATION

- Office of Patent and Trademark interference practice, **8:37.20**

### CREDIBILITY

- Disclosure, standard of proof of operability, **5:14**

### CRITICAL DATE OF INVENTION

- Novelty, nonobviousness and double patenting, **4:42**

### CRYSTALLINE PAROXETINE HYDROCHLORIDE HEMIHYDRATE

- Patent eligibility issues, **3:16**

### CULTIVATION

- Claim drafting, **7:31**
- Plants and plant patents, varieties found in “cultivated state,” **11:11**

### DATE

- Time or Date** (this index)

### DEFENSES

- Infringement, **6:26 to 6:32**

### DEFINITENESS REQUIREMENT

- Claim drafting, **7:2 to 7:6**

### DEPOSIT OF MICROORGANISMS

- Budapest Treaty
  - generally, **App B1 to App B4**
  - international depositary authorities under, **App B4**
- Office of Patent and Trademark, below
  - parties to treaty, **App B3**
- Disclosure** (this index)
- European Patent Convention
  - generally, **App D1 to App D5**
  - notice on recognition of microbiological experts for

### DEPOSIT OF MICROORGANISMS

#### —Cont'd

- European Patent Convention
  - Cont'd
    - purpose of EPC Rule 28, **App D5**
    - notice re. European patent applications and European patents in which reference is made to microorganisms, **App D4**
  - Rule 28 (amended), **App D2**
  - Rule 28 (original), **App D1**
  - Rule 28a, **App D3**
- European patents
  - European Patent Convention, above
    - patent cooperation treaty, information for PCT applicants designating—European Patent Organization, **App C4**
- Manual of Patent Examining Procedure § 608.01(p), **App A1**
- Office of Patent and Trademark
  - see also lines throughout this topic
  - advance notice of proposed rulemaking on deposit of biological materials, **App A2(2)**
- Budapest Treaty
  - certification of deposits made under Treaty, notice on request for, **App A5**
  - designation of international depositary authorities under Treaty, notice of, **App A3**
  - entry into force of Treaty, notice on, **App A4**
  - disclosure of deposit of biological materials, **5:35**
  - draft policy statement on deposit of biological materials, **App A2(1)**
- notice
  - Budapest Treaty, above in this group
  - designation of international depositary authorities under the Budapest Treaty, **App A3**

**DEPOSIT OF MICROORGANISMS**

—Cont'd

- Office of Patent and Trademark
  - Cont'd
  - notice—Cont'd
    - final rule on deposit of biological materials for patent purposes, **App A2(4)**
    - proposed rulemaking on deposit of biological materials for patent purposes, **App A2(3)**
  - rules and regulations, changes to time period for making necessary deposit of biological material, **App A6**
- Patent cooperation treaty
  - generally, **App C1 to App C4**
  - applicants' guide: Annex M1: references to deposits of microorganisms, **App C2**
  - applicants' guide, Annex M3, Form PCT/RO/134: Microorganisms, **App C3**
  - European Patent Organization, information for PCT applicants designating, **App C4**
  - microbiological inventions, **App C1**
- Rule on deposit of biological materials for patent purposes, 37 C.F.R. §§ 1.801 to 1.809, **App A2**
- Rules on applications, amendment, **App A7**
- Specification supplementation. **Disclosure** (this index)
- Suggestion for deposit of biological material, **App A1(1)**

**DERIVATION PROCEEDINGS AND DERIVED PATENTS SUITS**

- Plants and plant patents, derivation as element of infringement, **11:18**
- 2011 America Invents Act (AIA), **8:38**

**DESCRIPTION**

- Disclosure** (this index)

**DESIGN PATENTS**

- Animals and plants, design patent protection of ornamental features of, **9:5**

**DIAGNOSTIC METHODS**

- Patent eligibility issues, **3:11**

**DILIGENCE**

- Novelty, nonobviousness and double patenting, **4:63**

**DIRECT INFRINGEMENT**

- Generally, **6:14 to 6:16**

**DISCLOSURE**

- Generally, **5:1 et seq.**
- Animal data, **5:16, 5:17**
- Asserted or well-established utility, **5:10**
- Benefit to society, utility, **5:9**
- “Best mode” requirement, **5:29, 5:30**
- Budapest treaty, deposits under, **5:34, 5:50, 5:55**
- Case law
  - cell biology cases, **5:7.10, 5:24, 5:66**
  - description requirement, generally, **5:7 to 5:7.40**
  - immunology cases, **5:7.20, 5:25, 5:65**
  - medical device cases, **5:28.50**
  - microbiology cases, **5:7.10, 5:7.30**
  - miscellaneous biotechnology cases, **5:7.40**
  - molecular biology cases, **5:7.30, 5:26, 5:64**
  - pharmaceutical cases, **5:28.50**
  - time of deposit of biological materials, **5:40 to 5:43**
- Cell biology cases, **5:7.10, 5:24, 5:66**
- Clinical data, **5:15**
- Conventions, deposits under, **5:60, 5:61**
- Credibility, standard of proof of operability, **5:14**
- Date when deposit must be made available to public, **5:45 to 5:47**
- Deposit of biological materials
  - generally, **5:31 to 5:62**
  - Budapest treaty summary, **5:34**

## INDEX

### DISCLOSURE—Cont'd

- Deposit of biological materials
  - Cont'd
  - description in specification, **5:44**
  - history, **5:32**
  - location for deposit, **5:54 to 5:56**
  - new deposit rules, **5:56**
  - public availability restrictions, **5:48 to 5:52**
  - specification, means of
    - supplementing, **5:31 to 5:62**
  - summary of deposit rules, **5:33**
  - 35 U.S.C.A. § 112, satisfaction, **5:35 to 5:39, 5:59**
  - 35 U.S.C.A. § 114, authority of PTO to require specimens, **5:62**
  - time of deposit, **5:40 to 5:43**
  - time when deposit must be made available to public, **5:45 to 5:47**
  - treaties and conventions, **5:60, 5:61**
  - viability and operability issues, **5:53**
- Description
  - generally, **5:2 to 5:7.40**
  - biotechnology case law, **5:7 to 5:7.40**
  - deposits of biological materials, **5:44, 5:59**
  - 1998 interim guidelines, **5:3**
  - 1999 revised interim guidelines, **5:4**
  - training materials, **5:6, 5:6.50**
  - 2001 revised written description guidelines, **5:5**
  - written description, **5:5, 5:63 to 5:66**
- Enablement, generally, **5:8 to 5:28**
- European patent convention, **5:61**
- Evidence
  - animal data, **5:16, 5:17**
  - presumption of utility, **5:13**
  - standard of proof of operability, **5:14**
  - therapeutic utility, **5:15, 5:16, 5:18**
- Ex parte Lundak, **5:41**
- Final deposit rules, **5:52**

### DISCLOSURE—Cont'd

- Fully genotyped organisms, **5:38**
- Genetic engineered organisms, **5:39**
- Genotyped organisms, **5:38**
- Great Britain, **13:11, 13:12**
- Heightened written description, **5:2.10**
- Human therapeutic utility, **5:15, 5:16, 5:18**
- Hybridoma cell lines, **5:37**
- Immunology cases, **5:7.20, 5:25, 5:27, 5:65**
- Injurious inventions and utility, **5:19 to 5:20.10**
- In vitro data, **5:18**
- Isolated and mutated microorganisms, generally, **5:36**
- Licenses and licensing, **10:28**
- Limitations or restrictions on public availability, **5:48 to 5:52**
- Lists and listing, sequence listings, **5:67 to 5:69**
- Lundak case, **5:40 to 5:43**
- Medical device cases, **5:28.50**
- Microbiology cases, **5:7.10, 5:24, 5:66**
- Molecular biology cases, **5:7.30, 5:26, 5:64**
- Molecular immunology cases, **5:27**
- Mutated microorganisms, generally, **5:36**
- New deposit rules, deposits under, **5:56**
- Office of Patent and Trademark
  - deposit of biological materials, **5:35**
  - specimens, PTO authority to require, **5:62**
- Operable inventions, **5:12, 5:18, 5:21 to 5:28.50**
- Patent cooperation treaty, **5:60**
- Pharmaceutical cases, **5:28.50**
- Plants and plant patents, **11:14**
- Postfiling deposits, **5:43**
- Post-Lundak problems with postfiling deposits, **5:43**
- Pre-Lundak case law, **5:40**
- Presumption of utility, **5:13**
- Prima face case of inoperability, **5:13**

**DISCLOSURE—Cont'd**

- Proof. Evidence, above
- Public policy, inventions contrary to, **5:19, 5:20**
- Restrictions on public availability, **5:48 to 5:52**
- Safety of invention, **5:20**
- Sequence listings, **5:67 to 5:69**
- Specific and substantial utility, **5:11**
- Specification, deposit of
  - microbiological materials as means of supplementing, **5:31 to 5:56**
- Standard of proof of operability, **5:14**
- Substantial utility, **5:11**
- Therapeutic utility, evidence of, **5:15, 5:16, 5:18**
- 35 U.S.C.A. § 112, deposit of biological materials, **5:35 to 5:39, 5:59**
- 35 U.S.C.A. § 114, deposit of biological materials, **5:62**
- Time or date when deposit must be made available to public, **5:45 to 5:47**
- Training materials
  - 2000 written description training materials, **5:6**
  - 2008 written description training materials, **5:6.50**
- Treaties, deposits under, **5:34, 5:50, 5:55, 5:60, 5:61**
- Unsafe inventions, **5:20**
- Utility, generally, **5:8 to 5:21**
- Veterinary utility, animal data as proof of, **5:17**
- Viability, **5:53**
- Well-established utility, **5:10**
- Written description, **5:2.10, 5:5, 5:63 to 5:66**

**DISTINCTNESS**

- Office of Patent and Trademark, **8:22**
- Plants and Plant Patents** (this index)

**DNA**

- Copyright protection, DNA sequences, **14:3 to 14:6**

**DNA—Cont'd**

- MPEP § 708.02, petition to make special (Section VII. inventions relating to recombinant DNA), **App H6**
- Patent eligibility issues, **3:6**

**DNA SEQUENCES**

- Copyright protection, **14:3 to 14:6**

**DOCUMENTARY PRIOR ART**

- Novelty, nonobviousness and double patenting, **4:45 to 4:53**

**DOUBLE PATENTING**

- Novelty, Nonobviousness and Double Patenting** (this index)

**DRAFTING CLAIMS**

- Claim Drafting** (this index)

**DRAWINGS**

- Office of Patent and Trademark, **8:16 to 8:18.50**

**DRUG APPROVALS**

- Exclusive drug approvals, **14:12 to 14:16**
- Infringement, **6:33**

**EASTERN BLOC**

- Statutory protection, **13:1**

**ELECTRONIC PUBLICATIONS**

- Novelty, nonobviousness and double patenting, **4:50**

**EMPLOYEES**

- Ownership** (this index)

**ENABLEMENT**

- Disclosure** (this index)
- Novelty, nonobviousness and double patenting, “enabling” character, **4:45**
- Utility and injurious inventions, **5:20.10**

**ENERGY INVENTIONS**

- Ownership, **10:7**

**EQUITABLE CONDUCT**

- Office of Patent and Trademark, standards of inequitable conduct in biotechnology patent and prose-

## INDEX

**EQUITABLE CONDUCT—Cont'd**  
    cution litigation, **8:31**

**EQUIVALENTS, DOCTRINE OF**  
    **Infringement** (this index)

**ERYTHROPOIETIN**  
    **Infringement** (this index)

**ESTOPPEL**  
    Infringement, file wrapper estoppel,  
        **6:5 to 6:7**

**EUKARYOTIC CELL CULTURES**  
    Claim drafting, untransformed  
        eukaryotic cell cultures, **7:37**

**EUROPEAN PATENT CONVENTION**  
    Article 53: exceptions to patent-  
        ability, **App J1**  
    **Deposit of Microorganisms** (this  
        index)  
    Examination guidelines  
        microorganisms, inventions relat-  
        ing to, excerpts from Chapter  
        II, **App J2**  
        plant or animal varieties excluded  
        from patentability, excerpts  
        from Chapter IV, **App J3**  
    Microorganisms  
        **Deposit of Microorganisms** (this  
        index)  
        examination guidelines, inventions  
        relating to, excerpts from  
        Chapter II, **App J2**  
    Plant or animal varieties excluded  
        from patentability, excerpts from  
        Chapter IV, examination  
        guidelines, **App J3**

**EUROPEAN PATENTS**  
    Animals, utility patent protection  
        under European patents, **9:6**  
    **Deposit of Microorganisms** (this  
        index)  
    Disclosure, European patent conven-  
        tion, **5:61**

**EVIDENCE**  
    **Disclosure** (this index)

**EXAMINATION AND EXAMINATION GUIDELINES**

**European Patent Convention** (this  
        index)

    Interim examination guidelines for  
        species claims to chemical com-  
        positions based on single prior  
        art reference, **App H14**

**Manual of Patent Examining Pro-  
        cedure** (this index)

**Office of Patent and Trademark**  
        (this index)

    Training materials for examining  
        patent applications with respect  
        to 35 U.S.C Section 112,  
        chemical/biotechnical applica-  
        tions, **App H15**

    2011 America Invents Act (AIA),  
        supplemental examination, **8:39**

    Utility examination guidelines, **App  
        H26**

**EXCLUSIVE DRUG APPROVALS**  
    Generally, **14:12 to 14:16**

**EXHAUSTION DEFENSE**  
    Infringement, **6:29**

**EX PARTE MATTERS**  
    Disclosure, ex parte Lundak, **5:41**  
    Patentability of living organisms, **2:3,  
        2:4**

**EXPECTATION OF SUCCESS**  
    Nonobviousness, standard of, **4:22 to  
        4:24**

**EXPERIMENTAL USE DEFENSE**  
    Infringement, **6:26**

**EXPIRATION ISSUES**  
    Infringement, **6:22**

**EXTENSION OF PATENT TERM**  
    Infringement, **6:23**  
    Licenses and licensing, **10:27**

**FEDERAL GOVERNMENT**  
    **Licenses and Licensing** (this index)

**FEDERAL GOVERNMENT EMPLOYEES**  
    Ownership, **10:10**

- FERMENTATION**  
 Patent eligibility issues, **3:10**
- FERMENTATION PROCESSES**  
 Claim drafting, **7:25 to 7:29**  
 Living organisms, **3:4**
- FESTO DECISION**  
 Infringement, **6:6, 6:7**
- FIELD TESTING**  
 Novelty, nonobviousness and double  
 patenting: laboratory versus field  
 testing, **4:60**
- FILE WRAPPER ESTOPPEL**  
 Infringement, **6:5 to 6:7**
- FINAL DEPOSIT RULES**  
 Disclosure, **5:52**
- FINAL REJECTION**  
 Office of Patent and Trademark, **8:32**
- “FINGERPRINT” CLAIMS**  
 Claim drafting, **7:9**
- FIRST INVENTOR DEFENSE**  
 Infringement, **6:30**
- FLOOK DECISION**  
 Patentability of living organisms,  
 “unforeseen technologies,” **2:9**
- FOREIGN COUNTRIES**  
**International Matters** (this index)
- FORMAL DRAWINGS**  
 Office of Patent and Trademark, **8:16**  
 to **8:18.50**
- FRANCE**  
 International matters, **13:19**
- FULLY GENOTYPED  
 ORGANISMS**  
 Disclosure, **5:38**
- FUNCTIONAL LIMITATIONS**  
 Claim drafting in claims, **7:7**
- GATT**  
 Infringement, implementing legisla-  
 tion, **6:19**
- GATT—Cont’d**  
 Office of Patent and Trademark, post-  
 GATT transitional practice,  
**8:26, 8:32**
- GENERAL AGREEMENT ON  
 TARIFFS AND TRADE**  
**GATT** (this index)
- GENERIC ANIMAL DRUG AND  
 PATENT TERM  
 RESTORATION ACT**  
 Exclusive drug approvals, **14:13**
- GENES**  
 Claim drafting, structural genes and  
 their proteins, identification of,  
**7:16**  
 Copyright protection for gene  
 sequences or molecules, **14:2 to**  
**14:9**  
**Genetic Engineering** (this index)
- GENETIC ENGINEERING**  
 Animals, utility patent protection  
 under European patents, **9:6**  
 Claim drafting, **7:17**  
 Disclosure, **5:39**  
 Patents, generally, **1:3, 1:7**  
 Plant varieties, utility patent protec-  
 tion of, **9:2**
- GENETIC INVENTIONS**  
 PTO policy statement on, **App H22**
- GENOTYPED ORGANISMS**  
 Disclosure, **5:38**
- GENUS AND SPECIES  
 RESTRICTIONS**  
 Office of Patent and Trademark, **8:25**
- GEOGRAPHIC SCOPE OF U.S.  
 PATENTS**  
 Infringement, **6:25**
- GERMANY, FEDERAL REPUBLIC  
 OF**  
 Generally, **13:5 to 13:10**  
 “Antamanide” case, **13:10**  
 “Baker’s yeast” case, **13:7**  
 “Red dove” case, **13:6**  
 “Rose mutation” case, **13:8**

## INDEX

### **GERMANY, FEDERAL REPUBLIC OF—Cont'd**

“6-APA” case, **13:9**

### **GREAT BRITAIN**

Microbiological processes and microorganisms, **13:11, 13:12**

### **GROWTH HORMONES**

**Infringement** (this index)

### **GUARANTEES**

Infringement, patent term guarantees, **6:20**

### **GUIDELINES**

Patent eligibility issues, **3:17**

### **HAPTENS**

Claim drafting, **7:23**

### **HISTORICAL BACKGROUND**

Patent eligibility issues, **2:2**

### **HORMONES**

**Infringement** (this index)

### **HOUSE REPORT ON BIOTECHNOLOGICAL PROCESS PATENTS**

Generally, **App H12**

### **HUMANS**

Patentability of living organisms, **2:14**

### **HUMAN THERAPEUTIC UTILITY**

Disclosure, **5:15**

### **HYBRID CELL CULTURES**

Patents, **1:6**

### **HYBRIDOMA CELL LINES**

Claim drafting, **7:21**

Disclosure, **5:37**

### **IDENTIFICATION**

Claim drafting, identifying structural genes and their proteins, **7:16**

Licensed rights, **10:10**

### **IDENTITY LANGUAGE IN CLAIMS**

**Percentage Sequence Identity Language** (this index)

### **IMMUNOLOGY CASES**

Claim drafting, **7:19 to 7:24**

Classical immunology infringement cases, **6:10**

Disclosure, **5:7.20, 5:25, 5:27, 5:65**

**Infringement** (this index)

**Molecular Immunology Cases** (this index)

Nonobviousness standard, **4:32, 4:47**

### **IMPLIED LICENSES**

Generally, **10:34**

### **IMPLIED OBLIGATION TO ASSIGN**

Ownership, **10:3 to 10:5**

### **INDEPENDENT INVENTIONS**

Office of Patent and Trademark, **8:21**

### **INDUCEMENT**

**Infringement** (this index)

### **INEQUITABLE CONDUCT**

Cases, **8:31.50**

Office of Patent and Trademark, standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**

### **INFRINGEMENT**

Generally, **6:1 et seq.**

Active inducement and contributory infringement generally, **6:18**

plants and plant patents, **11:21**

America Invents Act (AIA) of 2011, prior use personal defense, **6:30.50**

ANDA or paper NDA, filing as infringing act, **6:28**

Antibodies, immunometric assays employing monoclonal antibodies, **6:12**

Antitrust matters, sham litigation, **6:35**

Biochemistry infringement cases, **6:8**

Biological product approval, effect of patents on, biosimilars, **6:33.50**

Biology infringement cases, **6:8**

Cell biology infringement cases, **6:9**

Claim drafting, **7:11**

**INFRINGEMENT—Cont'd**

- Classic “experimental use” defense, **6:26**
- Consent, Federal authorization and consent, **6:32**
- Construction or interpretation of claim in biotechnology patent infringement litigation, **6:8 to 6:13.50**
- Contributory infringement
  - generally, **6:17**
  - active inducement and contributory infringement, above
- Defenses, **6:26 to 6:32**
- Direct infringement, **6:14 to 6:16**
- Drug approval process, effect of patents on, **6:33**
- Equivalents, doctrine of
  - generally, **6:3**
  - reverse doctrine of equivalents, **6:4**
- Estoppel, file wrapper estoppel, **6:5 to 6:7**
- Exhaustion defense, **6:29**
- Experimental use defense, **6:26**
- Expiration issues, **6:22**
- Extension of patent term, **6:23**
- Federal authorization and consent, **6:32**
- Festo decision, **6:6, 6:7**
- File wrapper estoppel, **6:5 to 6:7**
- First inventor defense (1999 to 2011), **6:30**
- GATT implementing legislation, **6:19**
- Geographic scope of U.S. patents, **6:25**
- Guarantees of patent term, **6:20**
- Hormones. Growth hormones, above
- Immunology
  - classical immunology infringement cases, **6:10**
  - molecular immunology infringement cases, **6:12**
- Inducement. Active inducement and contributory infringement, above
- International matters
  - GATT implementing legislation, **6:19**

**INFRINGEMENT—Cont'd**

- International matters—Cont'd
  - International Trade Commission, enforcement of patent rights by, **6:34**
- Interpretation of claim in biotechnology patent infringement litigation, **6:8 to 6:13.50**
- Intervening rights, **6:24**
- Issuance issues, generally, **6:22**
- Limitations, **6:26 to 6:32**
- Literal infringement, **6:2**
- Medical and surgical procedures, limitations on infringement of patents on, **6:31**
- Medical device infringement cases, **6:13.50**
- Microbiology infringement cases, **6:9**
- Miscellaneous biotechnology infringement cases, **6:13**
- Molecular biology infringement cases, **6:11**
- Molecular immunology infringement cases, **6:12**
- Pandemic Readiness and Emergency Preparedness Act
  - contractor immunity, **6:36**
- Pharmaceutical infringement cases, **6:13.50**
- Pharmaceutical testing and Section 271(e)(1) defense, **6:27**
- Plants and Plant Patents** (this index)
- Prior activity-based personal defenses, **6:30, 6:30.50**
- Process patents, **6:16**
- Product patents, **6:15**
- Proinsulin vector, **6:18**
- Provisional rights, **6:21**
- Reissues and intervening rights, **6:24**
- Reverse doctrine of equivalents, **6:4**
- Section 271(e)(1) defense and pharmaceutical testing, **6:27**
- Section 271(e)(2), filing ANDA or paper NDA, **6:28**
- Sham litigation, antitrust matters, **6:35**
- Surgical procedures, limitations on infringement of patents on, **6:31**

## INDEX

### **INFRINGEMENT—Cont'd**

Temporal scope of U.S. patents, **6:19 to 6:24**

### **INJURIOUS INVENTIONS**

Disclosure, **5:19 to 5:20.10**

### **INTERFERENCE PRACTICE**

Authentication, **8:37.30**

Corroboration, **8:37.20**

Count, **8:37.40**

Pre-America Invents Act (AIA), **8:37**  
35 U.S.C.A. Section 135(b) requirements, **8:37.10**

### **INTERNATIONAL MATTERS**

Generally, **13:1 et seq.**

Antitrust matters, **13:13 to 13:17**

Australia, **13:15**

Canada, **13:17**

Eastern bloc, statutory protection in, **13:1**

France, **13:19**

**GATT** (this index)

**Germany, Federal Republic of** (this index)

Great Britain, **13:11, 13:12**

**Infringement** (this index)

Ireland, **13:16**

Japan, **13:18**

Licenses and licensing, **10:31**

Monopolies, **13:13 to 13:17**

New Zealand, **13:14**

**Office of Patent and Trademark**  
(this index)

**Plants and Plant Patents** (this index)

Third world, statutory protection in, **13:3**

Western block, statutory protection in, **13:2**

### **INTERNATIONAL TRADE**

#### **COMMISSION**

Infringement, **6:34**

### **INTER PARTES**

#### **REEXAMINATION**

#### **PROCEDURE**

Office of Patent and Trademark, **8:35**

### **INTER PARTES REVIEW**

Office of Patent and Trademark, post-AIA, **8:41**

### **INTERPRETATION**

Infringement litigation, interpretation of claim in, **6:8 to 6:13**

### **INTERVENING ART**

Novelty, nonobviousness and double patenting, **4:44**

### **INTERVENING RIGHTS**

Infringement, **6:24**

### **INVENTORSHIP**

Ownership, **10:1 to 10:10.50**

### **IN VITRO DATA**

Disclosure, **5:18**

### **IRELAND**

Microbiology cases, **13:16**

### **ISOLATED AND MUTATED MICROORGANISMS**

Claim drafting, pure cultures of microbial isolates, **7:32**

**Disclosure** (this index)

Patents, **1:2**

### **ISOLATION METHODS**

Claim drafting, **7:31**

### **JAPAN**

Generally, **13:18**

### **“JEPSON” CLAIMS**

Claim drafting, **7:14**

### **JOINT INVENTORSHIP**

Ownership, **10:10.50**

### **KNOWLEDGE**

Novelty, nonobviousness and double patenting, knowledge and suggestions of others, **4:67 to 4:70**

### **KSR CASE**

Novelty, nonobviousness and double patenting, **4:13, 4:14**

**LABORATORIES**

Novelty, nonobviousness and double patenting: laboratory versus field testing, **4:60**

**LANGUAGE USED IN CLAIMS**

Suggestions for resolution of apparent ambiguities created by use of percentage sequence identity language, **App H23**

**LENGTH**

Office of Patent and Trademark, sequence listing, **App F2(5)**

**LIBRARY COLLECTIONS**

Novelty, nonobviousness and double patenting, **4:48**

**LICENSES AND LICENSING**

Generally, **10:11 to 10:34**  
 Antitrust considerations, **10:32**  
 Biotechnology cases, **10:33**  
 Case law, **10:33**  
 Collaboration, **10:25**  
 Consideration, **10:19 to 10:23**  
 Disclosure, **10:28**  
 Extension of patent term, **10:27**  
 Federal licensing, generally, **10:30**  
 Identifying licensed rights, **10:10**  
 Implied license, **10:34**  
 International licensing, **10:31**  
 License to government, **10:35**  
 Maintenance, **10:26**  
 Milestone payments/timetables, **10:22**  
 Minimum royalties, **10:21**  
 Prosecution, **10:26**  
 Relaxation of payment obligations, **10:23**  
 Royalties, **10:20, 10:21**  
 Running royalties, **10:20**  
 Shop rights license, implied obligation to assign, **10:5**  
 Technical assistance, **10:25**  
 Termination, **10:24**  
 Time  
     generally, **10:13**  
     extension of patent term, **10:27**

**LICENSES AND LICENSING**

—**Cont'd**  
 Time—**Cont'd**  
     milestone payments/timetables, **10:22**  
     University licensing, **10:29**

**“LIFE FORM” PATENTS AND HUMAN SOCIETY**

Patentability of living organisms, **2:12**

**LIMITATIONS AND RESTRICTIONS**

Claim drafting, **7:7 to 7:8.50**  
 Contractual restrictions, tangible materials, **14:18**  
 Disclosure, restrictions on public availability, **5:48 to 5:52**  
 Double patenting, **4:69**  
 Infringement, **6:26 to 6:32**  
 Medical procedures, Appropriations Bill (HR 3610) containing patent limitations on, **App H13**  
 Obviousness, limitations on, **4:26, 4:70**  
 Office of Patent and Trademark, **8:20 to 8:26**

**LINKING CLAIMS**

Office of Patent and Trademark, **8:23**

**LISTS AND LISTING**

**Sequence Listings** (this index)

**LITERAL INFRINGEMENT**

Generally, **6:2**

**LIVING ORGANISMS**

Patents, **3:4**

**LOYALTY DUTY**

Ownership, implied obligation to assign, **10:4**

**LUNDAK CASE**

Disclosure, **5:40 to 5:43**

**MACROBIOLOGICAL PRODUCTS**

Patent eligibility issues, nonliving, **3:5**

**MAINTENANCE**

Licenses and licensing, **10:26**

## INDEX

### MANUAL OF PATENT

#### EXAMINING PROCEDURE

- Deposit of microorganisms, MPEP § 608.01(p), **App A1**
- DNA, MPEP § 708.02, petition to make special (Section VII. inventions relating to recombinant DNA), **App H6**

### MARKS AND MARKING

- Plants and plant patents, marking of protected varieties, **11:20**

### “MARKUSH GROUP” CLAIMS

- Claim drafting, **7:13**

### MATHEMATICAL STEPS

- Processes involving, patent eligibility issues, **3:14**

### MEDICAL AND SURGICAL PROCEDURES

- Appropriations Bill (HR 3610) containing patent limitations on, **App H13**
- Infringement, limitations on, **6:31**

### MEDICAL DEVICE CASES

- Disclosure, **5:28.50**
- Infringement, **6:13.50**
- Nonobviousness standard, **4:34**

### MEETINGS

- Novelty, nonobviousness and double patenting, **4:47**

### MENTAL STEPS

- Processes involving, patent eligibility issues, **3:14**

### MICROBIOLOGY CASES

- Canada, **13:17**
- Claim drafting, **7:25 to 7:38**
- Classical microbiology infringement cases, **6:9**
- Disclosure, **5:7.10, 5:24, 5:66**
- Great Britain, **13:11, 13:12**
- Ireland, **13:16**
- Nonobviousness standard, **4:28**

### MICROORGANISMS

- Deposit of Microorganisms (this index)

### MICROORGANISMS—Cont'd

- Great Britain, **13:11, 13:12**
- Isolated and Mutated Microorganisms** (this index)
- Novelty, nonobviousness and double patenting, released microorganisms: laboratory versus field testing, **4:60**
- PTO notice re. microorganisms—patentable subject matter, **App H1**

### MILESTONE

#### PAYMENTS/TIMETABLES

- Licenses and licensing, **10:22**

### MINIMUM ROYALTIES

- Licenses and licensing, **10:21**

### MIXED CULTURES

- Claim drafting, **7:33**

### MOLECULAR BIOLOGY

- Obviousness standard, **4:31**

### MOLECULAR BIOLOGY CASES

- Claim drafting, **7:15 to 7:18**
- Disclosure, **5:7.30, 5:26, 5:64**
- Infringement cases, **6:11**
- Nonobviousness standard, **4:30**

### MOLECULAR IMMUNOLOGY CASES

- Disclosure, **5:27**
- Nonobviousness standard, **4:32**

### MOLECULES

- Copyright protection for gene sequences or molecules, **14:2 to 14:9**

### MONOCLONAL ANTIBODIES

- Claim drafting, **7:20**

### MONOPOLIES

- Antitrust Matters** (this index)

### MOTIVATION

- Nonobviousness, standard of, **4:16**

### MPEP

- Manual of Patent Examining Procedure** (this index)

**MUTATED MICROORGANISMS**

Claim drafting, **7:35, 7:36**

**Isolated and Mutated Microorganisms** (this index)

**NASA-SPONSORED INVENTIONS**

Ownership, **10:8**

**NATURE, LAWS AND PRODUCTS OF**

Patent eligibility issues, **3:1 to 3:12**

**NEGATIVE LIMITATIONS**

Claim drafting, **7:8**

**NEGATIVE TEACHINGS**

Nonobviousness standard, negative teachings on expectations of success, **4:11**

**NEW DRUG APPLICATION**

Infringement, filing ANDA or paper NDA as infringing act, **6:28**

**NEWLY FOUND PLANTS VERSUS NEWLY CREATED PLANTS**

Generally, **11:5**

**NEW ZEALAND**

Generally, **13:14**

**1952 PATENT ACT**

Novelty, nonobviousness and double patenting  
introduction, **4:2**  
prior art, **4:38**

**1992 PATENT ACT**

Novelty, nonobviousness and double patenting  
documentary prior art—U.S.  
practice, **4:52**  
2002 amendments, **4:52**

**NONDOCUMENTARY PRIOR ART**

Novelty, nonobviousness and double patenting, **4:54 to 4:68**

**NOBVIOUSNESS**

**Novelty, Nonobviousness and Double Patenting** (this index)

**NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING**

1952 Patent Act

generally, **4:2, 4:3**

Generally, **4:1 et seq.**

Abandonment, suppression, or concealment, **4:65**

America Invents Act (AIA) of 2011

documentary prior art, U.S.

practice, **4:53**

effect of, **4:27**

introduction, **4:4**

prior art, **4:39**

Animal testing versus clinical testing, **4:59**

Appreciation, **4:64**

Artificial Intelligence, **4:71**

Biotechnology and selected chemical cases

novelty issues, **4:6**

Biotechnology novelty cases, misc., **4:10**

Cell biology cases, nonobviousness standard, **4:28**

Cell biology novelty cases, **4:7**

Chemical

cases

nonobviousness standard, **4:35**

novelty standard, **4:6**

compounds, structural similarities of, **4:15**

Classical microbiology novelty cases, **4:7**

Clinical testing versus animal testing, **4:59**

Competing approaches, **4:22**

Concealment, **4:65**

Conception, **4:62**

Conferences, **4:47**

Confidential documents, **4:49**

Copyright protection, novel gene sequences, **14:5, 14:9**

Critical date (pre AIA), **4:42**

Dates

critical date (pre AIA), **4:42**

date of invention (pre AIA), **4:41**

effective filing date, **4:43**

state of the art date, **4:40, 4:41**

## INDEX

### NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING

#### —Cont'd

- Defense of prior invention, **4:66**
- Diligence, **4:63**
- Documentary prior art, **4:45 to 4:53**
- Double patenting, **4:69**
- Effective filing date, **4:43**
- Electronic publications, **4:50**
- “Enabling” character, **4:45**
- Expectation of success, **4:19**
- Expectation of success, standard of nonobviousness, **4:22 to 4:24**
- Immunology cases, nonobviousness standard, **4:29, 4:32**
- Immunology novelty cases, **4:9**
- Intervening art, **4:44**
- Knowledge and suggestions of others, **4:67 to 4:70**
- KSR case
  - obviousness analysis, **4:14**
  - pre-KSR teaching-suggestion-motivation test, **4:13**
- Library collections, **4:48**
- Limitations on obviousness, **4:26, 4:70**
- Means of achieving results, **4:18**
- Medical device cases, nonobviousness standard, **4:34**
- Medical device novelty cases, **4:11**
- Meetings, **4:47**
- Microbiology cases, nonobviousness standard, **4:28**
- Miscellaneous, biotechnology cases, **4:33**
- Molecular biology, **4:8**
- Molecular biology cases, nonobviousness standard, **4:30**
- Molecular immunology cases, nonobviousness standard, **4:32**
- Motivation, standard of nonobviousness, **4:16**
- Negative teachings on expectations of success, **4:20**
- 1952 Patent Act
  - introduction, **4:2**
  - prior art, **4:38**
- 1992 Patent Act and 2002 amendments, documentary prior art—

### NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING

#### —Cont'd

- U.S. practice, **4:52**
- Nondocumentary prior art, **4:54 to 4:68**
- Obviousness/Molecular Biology, **4:31**
- Pharmaceutical cases, nonobviousness standard, **4:34**
- Pharmaceutical novelty cases, **4:11**
- Plant patent protection, **11:7, 11:9**
- Prima facie obviousness, **4:15 to 4:22**
  - means of achieving result, **4:18**
  - Recognition of problem, **4:17**
- Printed publications, **4:46 to 4:50**
- Prior art
  - generally, **4:36 to 4:44**
  - documentary prior art, **4:45 to 4:53**
  - interim examination guidelines for species claims to chemical compositions based on single prior art reference, **App H14**
  - 1952 Patent Act, **4:38**
  - 1992 Patent Act and 2002 amendments, U.S. practice, **4:52**
  - nondocumentary prior art, **4:54 to 4:68**
  - pre-2000 practice in U.S., **4:51**
  - 2011 America Invents Act, **4:39, 4:53**
  - U.S. patents and applications, **4:51 to 4:53**
- Prior invention of another, **4:54 to 4:66**
- Prior use and sale, **4:55**
- Processes, nonobviousness standard, **4:25**
- Protein chemistry, **4:8**
- Recognition of problem, **4:17**
- Reduction to practice, **4:58 to 4:61**
- Released microorganisms: laboratory versus field testing, **4:60**
- Sale, prior use and sale, **4:55**
- “Secondary considerations,” nonobviousness standard, **4:24**
- Secret documents, **4:49**

**NOVELTY, NONOBVIOUSNESS  
AND DOUBLE PATENTING**

**—Cont'd**

- Seminars, **4:47**
- Similarities, structural similarities of chemical compounds, **4:15**
- Standards
  - biotechnology novelty cases, misc., **4:10**
  - cell biology novelty cases, **4:7**
  - classical microbiology novelty cases, **4:7**
  - immunology novelty cases, **4:9**
  - medical device novelty cases, **4:11**
  - molecular biology, **4:8**
  - nonobviousness, **4:12 to 4:24**
  - novelty, **4:5**
    - biotechnology novelty cases, misc., **4:10**
    - cell biology novelty cases, **4:7**
    - classical microbiology novelty cases, **4:7**
    - immunology novelty cases, **4:9**
    - medical device novelty cases, **4:11**
    - molecular biology, **4:8**
    - pharmaceutical novelty cases, **4:11**
    - protein chemistry, **4:8**
    - pharmaceutical novelty cases, **4:11**
    - prima facie obviousness, **4:15 to 4:22**
    - protein chemistry, **4:8**
    - “secondary considerations,” **4:24**
    - “unexpected results,” **4:23**
- State of the art date, **4:40, 4:41**
- Statutory limitations on obviousness, **4:26**
- Structural similarities of chemical compounds, **4:15**
- Suggestions of others, **4:67 to 4:70**
- Suppression or concealment, **4:65**
- Teaching-suggestion-motivation test, nonobviousness standard, **4:13**
- Theory of “inventorship entity,” **4:37**
- Timing. Dates, above
- Trade shows, **4:47**
- “Unexpected results,” nonobviousness standard, **4:23**

**NOVELTY, NONOBVIOUSNESS  
AND DOUBLE PATENTING**

**—Cont'd**

- Unrealistic expectations of success, **4:21**
  - Utility, standard of nonobviousness, **4:16**
  - Vaccine cases, **4:61**
- NUCLEIC ACID**
- Office of Patent and Trademark, sequences, **App F2(12)**
- NUCLEOTIDE COMBINATIONS**
- Copyright protection, **14:8**
- NUCLEOTIDE SEQUENCES**
- Examination and examination guidelines, **App H27**
  - PTO final rule for submitting, **App H16**
  - Representation, **8:10**
  - Sequence Listings** (this index)
- NUMBERS AND NUMBERING**
- Plants and plant patents, number of claims, **11:16**
- NUTRIENT MEDIA**
- Claim drafting, **7:27**
- OBVIOUSNESS**
- Novelty, Nonobviousness and Double Patenting** (this index)
- OFFICE OF PATENT AND TRADEMARK**
- 1990 and 1998 Sequence Listing Rules, **App F2**
  - AIA. 2011 America Invents Act (AIA), below
  - America Invents Act (AIA) of 2011
    - derivation proceedings and derived patent suits, **8:38**
    - inter partes review, **8:41**
    - post-grant review, **8:40**
    - supplemental examination, **8:39**
  - Amino acid sequences, **App F2(11)**
  - Applications
    - coverage, **8:5**
    - foreign filed applications, domestic publication of, **8:34**

## INDEX

### OFFICE OF PATENT AND TRADEMARK—Cont'd

- Applications—Cont'd
  - provisional applications, **8:29**,  
**8:30**
  - sequence listing rules
    - 1990, **8:4.10**
    - 1998, **8:4.20**
- Atomic Energy Act, **8:27**
- Authentication, interference practice,  
**8:37.30**
- Continued examination, **8:33**
- Corroboration, interference practice,  
**8:37.20**
- Count, interference practice, **8:37.40**,  
**8:40**
- Deposit of Microorganisms** (this  
index)
- Disclosure** (this index)
- Distinct inventions, **8:22**
- Drafting considerations, **8:2 to**  
**8:18.50**
- Drawings, **8:16 to 8:18.50**
- Equitable conduct, standards of ineq-  
uitable conduct in biotechnology  
patent and prosecution litigation,  
**8:31**
- Examination
  - continued examination, **8:33**
  - deposit of microorganisms: Man-  
ual of Patent Examining Pro-  
cedure § 608.01(p), **App A1**
  - optional inter partes reexamination  
procedure, **8:35**
  - utility and utility patents, below  
**Written Description** (this index)
- Ex parte Chakrabarty, proceedings  
before patent office, **2:3**
- Final PTO utility examination  
guidelines, **App H9**
- Final rejection, **8:32**
- Final rule for submitting nucleotide  
sequences, **App H16**
- Formal drawings, **8:16 to 8:18.50**
- Formal processing, **App F2(13)**
- GATT, post-GATT transitional  
practice, **8:26, 8:32**
- Genetic inventions, PTO policy state-  
ment on, **App H22**

### OFFICE OF PATENT AND TRADEMARK—Cont'd

- Genus and species restrictions, **8:25**
- Guidelines
  - examination of patent applications  
under 35 U.S.C. 122, written  
description requirement, **App**  
**H25**
  - patent eligibility issues, **3:17**
- Independent inventions, **8:21**
- Inequitable conduct
  - cases, **8:31.50**
  - standards of inequitable conduct in  
biotechnology patent and  
prosecution litigation, **8:31**
- Interference practice
  - authentication, **8:37.30**
  - corroboration, **8:37.20**
  - count, **8:37.40**
  - pre-AIA, **8:37**
  - 35 U.S.C.A. Section 135(b)  
requirements, **8:37.10**
- International matters
  - GATT, post-GATT transitional  
practice, **8:26, 8:32**
  - publication of foreign filed  
applications, **8:34**
- Inter partes reexamination procedure,  
**8:35**
- Length of sequence listing, **App**  
**F2(5)**
- Linking claims, **8:23**
- Notices
  - animals—patentability, **App H4**
  - microorganisms—patentable  
subject matter, **App H1**
  - petitioning to make applications  
relating to biotechnology  
special, **App H5**
  - plant life—patentable subject mat-  
ter, **App H3**
- Nucleic acid sequences, **App F2(12)**
- Nucleotide sequences, PTO final rule  
for submitting, **App H16**
- Optional inter partes reexamination  
procedure, **8:35**
- Petitions
  - generally, **8:19**

**OFFICE OF PATENT AND  
TRADEMARK—Cont'd**

- Petitions—Cont'd
  - MPEP § 708.02, petition to make special (Section VII. inventions relating to recombinant DNA), **App H6**
  - notice, petitioning to make applications relating to biotechnology special, **App H5**
- Photographic figures, **8:17**
- Post-GATT transitional practice, **8:26, 8:32**
- Post-grant review, post-AIA, **8:40**
- Post-issuance considerations, **8:35**
- Practice and procedure, generally, **8:1 et seq.**
- Prioritized examination, **8:18.50**
- Prosecution considerations, generally, **8:19 to 8:41**
- Provisional applications, **8:29, 8:30**
- Publication of foreign filed applications, **8:34**
- Reexamination, inter partes reexamination procedure, **8:35**
- Rejection, **8:32**
- Rejoinder of method claims to product claims, **8:24**
- Restrictions, **8:20 to 8:26**
- Sequence Listings** (this index)
- Species restrictions, **8:25**
- Standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**
- Strandedness of sequence listings, **App F2(7)**
- Support of government, mention of, **8:3**
- Suspension of prosecution, **8:28**
- 35 U.S.C.A. Section 135(b) requirements, interference practice, **8:37.10**
- Topology of sequence listings, **App F2(8)**
- Utility and utility patents
  - examination and examination guidelines
    - generally, **App H26**

**OFFICE OF PATENT AND  
TRADEMARK—Cont'd**

- Utility and utility patents—Cont'd
  - examination and examination guidelines—Cont'd
    - final PTO utility examination guidelines, **App H9**
    - nucleotide sequences, **App H27**
    - proposed utility examination guidelines at 60 FR 97, **App H10**
    - revised interim utility guidelines training materials, **App H21**
    - revised utility examination guidelines, request for comments, **App H20**
    - synopsis of utility examination guidelines, **App H11**
  - Written Description** (this index)
- OPERABLE INVENTIONS**
  - Disclosure, **5:12, 5:18, 5:21 to 5:28.50**
- OPERATING CONDITIONS**
  - Claim drafting, **7:28**
- OPTIONAL INTER PARTES REEXAMINATION PROCEDURE**
  - Office of Patent and Trademark, **8:35**
- ORGAN CULTURES**
  - Claim drafting, **7:38**
  - Patents, **1:5**
- “ORGANISM-PLUS-CARRIER” CLAIMS**
  - Claim drafting, **7:34**
- ORNAMENTAL FEATURES**
  - Animals and plants, design patent protection of ornamental features of, **9:5**
- ORPHAN DRUG ACT**
  - Exclusive drug approvals, **14:15**
- OWNERSHIP**
  - Generally, **10:1 et seq.**
  - Assignment, **10:2 to 10:5**

## INDEX

### OWNERSHIP—Cont'd

- Correction of inventorship errors, **10:1.50**
- Employees
  - federal government employees, inventions made by, **10:10**
  - implied obligation to assign, **10:3**
- Energy inventions, **10:7**
- Federal government employees, inventions made by, **10:10**
- Federal statutes, **10:7 to 10:10**
- Implied obligation to assign, **10:3 to 10:5**
- Inventorship, generally, **10:1 to 10:1.50**
- Joint inventorship, **10:10.50**
- Loyalty duty, implied obligation to assign, **10:4**
- NASA-sponsored inventions, **10:8**
- Plants and plant patents, **11:12**
- Shop rights license, implied obligation to assign, **10:5**
- State statutes, **10:6**
- Support of government, inventions made with, **10:9**
- Testing of compounds, inventorship, **10:1.10**
- Unexpected results, inventorship, **10:1.20**
- Written description or utility, inventorship, **10:1.30**

### PANDEMIC READINESS AND EMERGENCY PREPAREDNESS ACT

- Infringement
  - contractor immunity, **6:36**

### PATENT AND TRADEMARK OFFICE

- Office of Patent and Trademark (this index)

### PATENT COOPERATION TREATY

- Deposit of Microorganisms (this index)

### PATENT ELIGIBILITY ISSUES

- Generally, **2:1 et seq.**
- Antibodies, **3:7**
- Bergy decision, **2:4, 2:5**

### PATENT ELIGIBILITY ISSUES

#### —Cont'd

- Biochemicals, **3:8**
- CCPA, **2:5 to 2:7**
- Cells in vitro, non fermentation process, **3:12**
- Chakrabarty decision, **2:6, 2:8**
- Computer-implemented steps, processes involving, **3:14**
- Consolidation of proceedings, **2:7**
- Crystalline paroxetine hydrochloride hemihydrate, **3:16**
- Diagnostic methods, **3:11**
- DNA, **3:6**
- Early developments, **2:2**
- Ex parte Chakrabarty, proceedings before Office of Patent and Trademark, **2:3**
- Ex parte matters, **2:3, 2:4**
- Fermentation, **3:10**
- Flook decision and “unforeseen technologies,” **2:9**
- Guidelines, PTO, **3:17**
- Human organisms, **2:14**
- “Life form” patents and human society, **2:12**
- Living organisms, **3:4**
  - biotechnology, U.S. materials on, **App H8**
  - per se, **2:1 et seq.**
  - subject matter, U.S. materials on, **App H2**
- Macrobiological products, nonliving, **3:5**
- Mathematical steps, processes involving, **3:14**
- Mental steps, processes involving, **3:14**
- Nature, laws and products of, **3:1 to 3:12**
- Non fermentation process, cells in vitro, **3:12**
- Nonliving macrobiological products, **3:5**
- Other chemicals, **3:8**
- Peptides, **3:7**
- Plants and plant patents, **2:10**
- Printed matter, **3:15**

**PATENT ELIGIBILITY ISSUES**

—**Cont'd**

- Processes involving mental, mathematical or computer-implemented steps, **3:14**
- Proteins, **3:7**
- Remand, **2:7**
- RNA, **3:6**
- Static v. dynamic construction, **2:11**
- Statutory subject matter, **2:1**
- Supreme Court, **2:7, 2:8, 3:2**
- Treatment methods, **3:13**
- Unforeseen technologies, **2:9**
- Vitalism, **2:13**

**PATENTS**

- As to particular patent matters, see specific index topics
- Generally, **1:1 et seq.**
- Cell cultures, **1:5, 1:6**
- Eligibility. **Patent Eligibility Issues** (this index)
- European Patent Convention** (this index)
- Extension of Patent Term** (this index)
- Fundamental patent law concepts, **1:8**
- Genetic Engineering** (this index)
- Hybrid cell cultures, **1:6**
- Infringement** (this index)
- Isolated and mutated microorganisms, **1:2**
- Mutated microorganisms, **1:2**
- Novelty, Nonobviousness and Double Patenting** (this index)
- Office of Patent and Trademark** (this index)
- Organ cultures, **1:5**
- Plants and Plant Patents** (this index)
- Tissue cultures, **1:5**
- Trade secrets, patents, and genetic engineering industry, **1:7**
- Utility and Utility Patents** (this index)
- Vaccines** (this index)

**PEDIATRIC EXCLUSIVITY**

- Protection for biotechnology, **14:16**

**PEOPLE**

- Patentability of living organisms, **2:14**

**PEPTIDES**

- Patent eligibility issues, **3:7**

**PERCENTAGE SEQUENCE IDENTITY LANGUAGE**

- Metes and bounds of claims reciting, **App H24**
- Suggestions for resolution of apparent ambiguities created by use in claims, **App H23**

**PETITIONS**

- Office of Patent and Trademark** (this index)

**PHARMACEUTICAL CASES**

- Disclosure, **5:28.50**
- Infringement, **6:13.50**
- Nonobviousness standard, **4:34**

**PHARMACEUTICAL TESTING**

- Infringement, Section 271(e)(1) defense, **6:27**

**PHOTOGRAPHIC FIGURES**

- Office of Patent and Trademark, **8:17**

**PLANTS AND PLANT PATENTS**

- Generally, **11:1 et seq.**
- Active inducement and contributory infringement, **11:21**
- “Asexually reproduced” varieties, **11:10**
- Bacteria, **11:3**
- Breadth of claims, **11:16**
- Changes in plant patent protection under UPOV, **11:23**
- Claims for plant products, generally, **11:15**
- Comparison of plant variety protection methods, **12:5**
- Conception and reduction to practice, **11:13**
- Contributory infringement, **11:21**
- Conventions, plant patent protection outside of, **13:4**
- Copyright protection for plant and animal phenotypes, **14:10**

## INDEX

### PLANTS AND PLANT PATENTS

#### —Cont'd

- Courts, application of PVPA in, **12:3**
- “Cultivated state,” varieties found in, **11:11**
- Derivation as element of infringement, **11:18**
- Disclosure requirements, **11:14**
- Distinctness
  - generally, **11:8**
  - infringement, **11:19**
- European Patent Convention, examination guidelines, plant or animal varieties excluded from patentability, **App J3**
- Infringement, generally, **11:17**
- International matters
  - conventions, plant patent protection outside of, **13:4**
  - UPOV countries, plant variety protection in, **12:6**
- Marking of protected varieties, **11:20**
- Newly found plants versus newly created plants, **11:5**
- Novelty and nonobviousness, **11:7, 11:9**
- Number and breadth of claims, **11:16**
- Ownership, **11:12**
- Patentability of living organisms, **2:10**
- Plant variety protection
  - certificate application, **App G4**
  - office, **12:4**
- PTO notice, plant life—patentable subject matter, **App H3**
- Restoration of plant patent term, **11:22**
- Scope of variety protection, **12:2**
- Tuber-propagated plants, **11:4**
- Union for protection of new varieties of plants. UPOV, below
- UPOV
  - generally, **12:1 et seq.**
  - changes in plant patent protection under UPOV, **11:23**
- Utility patents, **9:1 to 9:3, 9:5**
- Variety protection. **Plant Variety Protection Materials** (this index)

### PLANTS PATENT ACT

Generally, **11:2 to 11:5**

### PLANT VARIETY PROTECTION MATERIALS

- Application for plant variety protection certificate, **App G4**
- Guidelines
  - Exhibit A: Origin and Breeding history, **App G3(A)**
  - Exhibit B: Statement of distinctness, **App G3(B)**
  - Exhibit E: Statement of the basis of ownership, **App G3(E)**
- PVPA regulations and rules of practice, **App G2**
- United States Plant Variety Protection Act, generally, **App G1**

### POSTFILING DEPOSITS

Disclosure, **5:43**

### POST-GATT TRANSITIONAL PRACTICE

Office of Patent and Trademark, **8:26, 8:32**

### POST-GRANT REVIEW

Office of Patent and Trademark, post-AIA, **8:40**

### POST-ISSUANCE

#### CONSIDERATIONS

Office of Patent and Trademark, **8:35**

### PREAMBLE LIMITATIONS

Claim drafting, **7:8.50**

### PRESUMPTIONS

Disclosure, presumption of utility, **5:13**

### PRIMA FACIE CASE OR MATTERS

- Disclosure, prima face case of inoperability, **5:13**
- Nonobviousness, standard of, **4:15 to 4:22**

### PRINTED MATTER

Patent eligibility issues, **3:15**

**PRINTED PUBLICATIONS**

Novelty, nonobviousness and double patenting, **4:46 to 4:50**

**PRIOR ART**

Novelty, Nonobviousness and Double Patenting (this index)

**PRIOR INVENTION OF ANOTHER**

Novelty, nonobviousness and double patenting, **4:54 to 4:66**

Reduction to practice

generally, **4:58 to 4:61**

actual, **4:58**

animal versus clinical testing, **4:59**

constructive, **4:57**

early vaccine cases, **4:61**

released microorganisms, **4:60**

**PRIOR USE AND SALE**

Novelty, nonobviousness and double patenting, **4:55**

**PROCESSES**

Claim drafting, “product-by-process” claims, **7:10 to 7:12**

Infringement, process patents, **6:16**

Mental, mathematical or computer-implemented steps, patent eligibility issues, **3:14**

Nonobviousness standard, **4:25**

**PRODUCT PATENTS**

Infringement, **6:15**

New processes and uses, coverage of, **6:15**

**PROINSULIN VECTOR**

Infringement, **6:18**

**PROOF**

Disclosure (this index)

**PROSECUTION**

**CONSIDERATIONS**

Licenses and licensing, **10:26**

Office of Patent and Trademark (this index)

**PROTEINS**

Claim drafting, structural genes and their proteins, identification of, **7:16**

**PROTEINS—Cont’d**

Copyright protection, **14:6**

Patent eligibility issues, **3:7**

**PROVISIONAL APPLICATIONS**

Office of Patent and Trademark, **8:29, 8:30**

**PROVISIONAL RIGHTS**

Infringement, **6:21**

**PTO**

Office of Patent and Trademark (this index)

**PUBLICATION**

Office of Patent and Trademark, domestic publication of foreign filed applications, **8:34**

**PUBLIC POLICY**

Disclosure, inventions contrary to public policy, **5:19, 5:20**

**PURE CULTURES OF MICROBIAL ISOLATES**

Claim drafting, **7:32**

**REAGENTS**

Claim drafting, **7:24**

**“RED DOVE” CASE**

Germany, Federal Republic of, **13:6**

**REEXAMINATION**

Office of Patent and Trademark, inter partes reexamination procedure, **8:35**

**REISSUES**

Infringement, **6:24**

**REJECTION**

Office of Patent and Trademark, **8:32**

**REJOINER**

Office of Patent and Trademark, rejoinder of method claims to product claims, **8:24**

**RELEASED MICROORGANISMS**

Novelty, nonobviousness and double patenting: laboratory versus field testing, **4:60**

## INDEX

### REMAND

Patent eligibility issues, **2:7**

### REPORTS AND REPORTING

Trilateral Project 24.1, comparative study/report on biotechnology patent practices, **App J5**

### RESTORATION

Plant patent term, **11:22**

### RESTRICTIONS

**Limitations and Restrictions** (this index)

### REVERSE DOCTRINE OF EQUIVALENTS

Infringement, **6:4**

### RNA

Patent eligibility issues, **3:6**

### “ROSE MUTATION” CASE

Germany, Federal Republic of, **13:8**

### ROYALTIES

Licenses and licensing, **10:20, 10:21**

### RUNNING ROYALTIES

Licenses and licensing, **10:20**

### SAFETY

Disclosure, unsafe inventions, **5:20**

### SALES

Novelty, nonobviousness and double patenting, prior use and sale, **4:55**

### “SECONDARY CONSIDERATIONS”

Nonobviousness standard, **4:24**

### SECRET DOCUMENTS

Novelty, nonobviousness and double patenting, **4:49**

### SEMINARS

Novelty, nonobviousness and double patenting, **4:47**

### SEQUENCE LISTINGS

Generally, **App F**  
Disclosure, **5:67 to 5:69**

### SEQUENCE LISTINGS—Cont’d

Draft sequence listing rules, **App F1(1)**

Nucleotide sequence and/or amino acid sequence disclosures, requirements for patent applications containing

generally, 37 C.F.R. §§ 1.821 to 1.825, **App F1, App F1(6)**

PTO notices. Office of Patent and Trademark, below

Office of Patent and Trademark generally, **8:18**

amendments, 2021, **8:4.40**

amino acid representation, **8:11**

compact disc regulations, **8:4.30**

coverage, **8:5**

feature keys, **8:12**

format, **8:6**

general information, part of sequence listing XML, **8:7**

nucleotide sequence and/or amino acid sequence disclosures, requirements for patent applications containing

notices

final rule, **App F1(3)**

proposed rules, **App F1(2), App F1(4)**

rules, **App F1(2), App F1(4), App F1(5)**

nucleotide sequence representation, **8:10**

rules, 1990, **8:4.10**

rules, 1998, **8:4.20**

sequence data, part of sequence listing XML, **8:8**

sequence representation, generally, **8:9**

transition, WIPO Standard ST.26, **8:4.50**

XML, **8:7, 8:8, 8:13, 8:14**

**Percentage Sequence Identity Language** (this index)

Standard for presentation of nucleotide and amino acid, using extensible markup language in patent applications, **App F3**

**SHAM LITIGATION**

Infringement, antitrust matters, **6:35**

**SIMILARITIES**

Nonobviousness standard, structural similarities of chemical compounds, **4:15**

**“6-APA” CASE**

Germany, Federal Republic of, **13:9**

**SPECIAL CLAIM FORMATS**

Claim drafting, **7:9 to 7:14**

**SPECIES RESTRICTIONS**

Office of Patent and Trademark, **8:25**

**SPECIFIC AND SUBSTANTIAL UTILITY**

Disclosure, **5:11**

**SPECIFICATIONS**

Disclosure, deposit of microbiological materials as means of supplementing specification, **5:31 to 5:56**

**SPECIMENS**

Disclosure, PTO authority to require specimens, **5:62**

**STANDARD OF PROOF**

Disclosure, standard of proof of operability, **5:14**

**STANDARDS**

**Novelty, Nonobviousness and Double Patenting** (this index)

Office of Patent and Trademark, standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**

**STATIC v. DYNAMIC CONSTRUCTION**

Patentability of living organisms, **2:11**

**STRANDEDNESS**

Office of Patent and Trademark, sequence listing, **App F2(7)**

**STRUCTURAL GENES AND THEIR PROTEINS**

Claim drafting, identification, **7:16**

**STRUCTURAL SIMILARITIES**

Nonobviousness standard, structural similarities of chemical compounds, **4:15**

**STUDIES**

Trilateral Project 24.1, comparative study on biotechnology patent practices, **App J5**

**SUBSTANTIAL UTILITY**

Disclosure, **5:11**

**SUGGESTIONS**

Novelty, nonobviousness and double patenting, knowledge and suggestions of others, **4:67 to 4:70**  
Suggestions of others, **4:68**

**SUPPLEMENTAL EXAMINATION**

America Invents Act (AIA) of 2011, **8:39**

**SUPPLEMENTARY PROTECTION**

Claim drafting, **7:29**

**SUPPORT OF GOVERNMENT**

Office of Patent and Trademark, mention of government support, **8:3**  
Ownership, inventions made with government support, **10:9**

**SUPPRESSION**

Novelty, nonobviousness and double patenting, **4:65**

**SUPREME COURT**

Patentability of living organisms, **2:7, 2:8**  
Patent eligibility issues, **3:2**

**SURGICAL PROCEDURES**

Infringement, limitations on, **6:31**

**SUSPENSION OF PROSECUTION**

Office of Patent and Trademark, **8:28**

**TANGIBLE PROPERTY RIGHTS**

Cell lines, **14:11**

**TAXONOMIC CLASSIFICATION OF ORGANISMS**

Claim drafting, **7:4**

## INDEX

### **TECH CENTER 1600**

Background information on examining tech center 1600, biotechnology, **App H7**

### **TECHNICAL ASSISTANCE**

Licenses and licensing, **10:25**

### **TEMPORAL SCOPE OF U.S. PATENTS**

Infringement, **6:19 to 6:24**

### **TERMINATION**

Licenses and licensing, **10:24**

### **TEST KITS**

Claim drafting, **7:24**

### **THERAPEUTIC UTILITY**

Disclosure, **5:15, 5:16, 5:18**

### **THIRD WORLD**

Statutory protection, **13:3**

### **TIME OR DATE**

Disclosure, time or date when deposit must be made available to public, **5:45 to 5:47**

**Extension of Patent Term** (this index)

Infringement, extension of patent term, **6:23**

**Licenses and Licensing** (this index)

**Novelty, Nonobviousness and Double Patenting** (this index)

### **TISSUE CULTURES**

Claim drafting, **7:38**

Patents, **1:5**

### **TITLE AND OWNERSHIP**

**Ownership** (this index)

### **TOPOLOGY**

Office of Patent and Trademark, sequence listings, **App F2(8)**

### **TRADE SECRETS**

Generally, **14:1**

Patents and genetic engineering industry, **1:7**

### **TRADE SHOWS**

Novelty, nonobviousness and double patenting, **4:47**

### **TRAINING MATERIALS**

Disclosure, **5:6, 5:6.50**

Examining patent applications with respect to 35 U.S.C Section 112, chemical/biotechnical applications, **App H15**

Revised interim written description guidelines, **App H19**

2000 written description training materials, **5:6**

2008 written description training materials, **5:6.50**

### **TREATIES**

**Budapest Treaty** (this index)

Disclosure, deposits under, **5:34, 5:50, 5:55, 5:60, 5:61**

### **TREATMENT METHODS**

Patent eligibility issues, **3:13**

### **TUBER-PROPAGATED PLANTS**

Generally, **11:4**

### **U. S. PATENT AND TRADEMARK OFFICE**

**Office of Patent and Trademark** (this index)

### **“UNEXPECTED RESULTS”**

Nonobviousness standard, **4:23**

### **UNFORESEEN TECHNOLOGIES**

Patent eligibility issues, **2:9**

### **UNION FOR PROTECTION OF NEW VARIETIES OF PLANTS**

**Plants and Plant Patents** (this index)

### **UNITED STATES PATENT AND TRADEMARK OFFICE**

**Office of Patent and Trademark** (this index)

### **UNITED STATES PLANT VARIETY PROTECTION ACT**

**Plant Variety Protection Materials** (this index)

### **UNIVERSITY LICENSING**

Generally, **10:29**

**UNREALISTIC EXPECTATIONS**

Nonobviousness standard, unrealistic expectations of success, **4:21**

**UNSAFE INVENTIONS**

Disclosure, **5:20**

**UNTRANSFORMED  
EUKARYOTIC CELL  
CULTURES**

Claim drafting, **7:37**

**UPOV**

**Plants and Plant Patents** (this index)

**UTILITY AND UTILITY PATENTS**

Animal varieties, **9:3 to 9:6**

**Disclosure** (this index)

Enablement, **5:20.10**

Guidelines

generally, **App H26**

revised interim utility guidelines

training materials, **App H21**

revised utility examination

guidelines, request for comments, **App H20**

Nonobviousness, standard of, **4:16**

**Office of Patent and Trademark** (this index)

Plant patents, **9:1 to 9:3, 9:5**

**VACCINES**

Generally, **1:4**

**Infringement** (this index)

Novelty, nonobviousness and double patenting, **4:61**

Patents, generally, **1:4**

**VETERINARY UTILITY**

Disclosure, animal data as proof of veterinary utility, **5:17**

**VIABILITY**

Disclosure, **5:53**

**VITALISM**

Patent eligibility issues, **2:13**

**WAXMAN-HATCH ACT**

Drug approvals, **14:12**

**WELL-ESTABLISHED UTILITY**

Disclosure, **5:10**

**WESTERN BLOCK**

Statutory protection, **13:2**

**WIPO STANDARD ST.25**

Generally, **App J4**

Adoption of updated, revision to incorporation by reference, **App F3(1)**

**WRITTEN DESCRIPTION**

Disclosure, **5:2.10, 5:5, 5:63 to 5:66**

Examination of patent applications under 35 U.S.C. 112. See entries throughout this topic

Guidelines for examination of patent applications under 35 U.S.C. 122, **App H25**

Office of Patent and Trademark. See entries throughout this topic

Request for comments on interim guidelines for examination of patent applications under 35 U.S.C. 112 “written description” requirement, **App H17, App H18**

Revised interim written description guidelines, training materials, **App H19**

Training materials, revised interim written description guidelines, **App H19**